Final overall survival (OS) analysis of a multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-RT) without elective nodal irradiation with chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung cancer (NSCLC).
Hidehito Horinouchi(Tokyo National Hospital), Yuichiro Ohe(National Cancer Center), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Naoki Ishizuka(Iwate Medical University), Ikuo Sekine(University of Tsukuba), Hisayasu Nagakura(NTT Medical Center), Toshinori Soejima(Hyogo Ion Beam Medical Center), Tomohide Tamura(St. Luke's International Hospital), Nishiyama Noriaki(Hokkaido University), Masao Harada(Shikoku Cancer Center), Hiroshi Isobe
Cited by 0
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|Annals of Oncology|2012|555
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537